

## *p*-TSA-Promoted Efficient Synthesis of Some New Thiophene Hybridized Thiadiazolyl Schiff Bases as Antibacterial Agents

Geeta Mishra<sup>1,2</sup>, Parmesh K. Dwivedi<sup>1\*</sup>, Neeraj Verma<sup>3</sup>, Sajal Srivastava<sup>1</sup>, Ashok K. Singh<sup>1</sup> and Devdutt Chaturvedi<sup>4</sup>

<sup>1</sup>Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector-125, Noida, Uttar Pradesh, India

<sup>2</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, Lucknow, Uttar Pradesh, India

<sup>3</sup>Department of Pharmacology, Hygia College of Pharmacy, Lucknow, Uttar Pradesh, India

<sup>4</sup>Department of Chemistry, School of Physical Sciences, Mahatma Gandhi Central University, Motihari (East Champaran), Bihar, India

**ABSTRACT** A new series of thiophene hybridized thiadiazolyl Schiff bases was designed and synthesized employing FeCl<sub>3</sub>-mediated cyclization of thiosemicarbazone into thiadiazoles and their subsequent Schiff bases formation using *p*-TSA in benzene. To understand the interaction of the proposed compounds with  $\beta$ -lactamase (Protein Data Bank [PDB] ID: 3UDI), a molecular docking was performed. All the compounds demonstrated an optimal binding affinity with  $\beta$ -lactamase (−8.17 to −9.75 kcal/mol) and showed crucial hydrogen bonds and  $\pi$ – $\pi$  interaction with the leading amino acids Arg298, Ala300, and Val391 located at the active site of  $\beta$ -lactamase. The *in vitro* antibacterial activity of the desired molecules was conducted against few gram-positive and Gram-negative bacterial strains using amoxicillin as reference drug. The compound having *p*-hydroxyphenyl substituent (**3c**) was found to be potentially effective to inhibit *P. aeruginosa* and *E. coli* with MIC value 7.5  $\mu$ g/mL and 9.0  $\mu$ g/mL, respectively, whereas other compounds exhibited moderate to good activity. Altogether, the primary *in-vitro* screening of newly synthesized thiophene hybridized thiadiazole Schiff bases opens a new venture towards the development of promising alternatives of  $\beta$ -lactamase inhibitors as anti-bacterial agents.

**KEYWORDS** Antibacterial activity, FeCl<sub>3</sub>-mediated cyclization, *p*-TSA-catalyzed synthesis, Thiophene-Thiadiazolyl Schiff base,  $\beta$ -Lactamase inhibitors.

**How to cite this article:** Mishra, G., Dwivedi, P.K., Verma, N., Srivastava, S., Singh, A.K. and Chaturvedi, D. *p*-TSA-Promoted Efficient Synthesis of Some New Thiophene Hybridized Thiadiazolyl Schiff Bases as Antibacterial Agents, *Indian J. Heterocycl. Chem.*, **2023**, 33, 361–368. (<https://doi.org/10.59467/IJHC.2023.33.361>)

### INTRODUCTION

Since the invention of penicillin, the development of bacterial resistance to antibiotics has been a significant issue.  $\beta$ -Lactam antibiotics incorporate 60% of all the antibiotics used worldwide and are considered one of the best treatment options.<sup>[1]</sup> Thus, the inhibition of  $\beta$ -lactamase ( $\beta$ -lactam-hydrolyzing enzyme) is thought to be the most significant and precise mechanism of bacterial resistance.<sup>[2]</sup> A significant contribution was made by  $\beta$ -lactam antibiotics towards the

treatment and cure of bacterial infections<sup>[3]</sup>, however, their overuse has led to the gradual occurrence of various types of bacterial resistance.<sup>[4,5]</sup> The need for the discovery of novel antibiotics that are effective in treating bacterial infections is due to their high frequency and quick transmission.<sup>[6]</sup> Another reason is to overcome resistance and decrease their own toxicity and side effects.<sup>[5]</sup> Clavulanic acid, sulbactam, and tazobactam are the three most often used  $\beta$ -lactamase inhibitors, which share a  $\beta$ -lactam backbone in common. As a result, these inhibitors prevent  $\beta$ -lactamases from

\*Corresponding author: Email: [pkdwivedi@lko.amity.edu](mailto:pkdwivedi@lko.amity.edu)